The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
28523115 |
59 |
Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP |
Novartis Institutes For Biomedical Research |
28169162 |
86 |
Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
Askat |
28105284 |
55 |
Discovery of Novel Seven-Membered Prostacyclin Analogues as Potent and Selective Prostaglandin FP and EP3 Dual Agonists. |
Ono Pharmaceutical |
26985320 |
89 |
Discovery of G Protein-Biased EP2 Receptor Agonists. |
Ono Pharmaceutical |
27133594 |
6 |
Piperidine derivatives as nonprostanoid IP receptor agonists 2. |
Toray Industries |
26996371 |
27 |
Piperidine derivatives as nonprostanoid IP receptor agonists. |
Toray Industries |
27055938 |
82 |
Structural optimization and structure-functional selectivity relationship studies of G protein-biased EP2 receptor agonists. |
Ono Pharmaceutical |
24021582 |
52 |
Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. |
Novartis Institutes For Biomedical Research |
17236765 |
6 |
Identification of novel glycine sulfonamide antagonists for the EP1 receptor. |
Glaxosmithkline |
24900213 |
25 |
Novel 3-Oxazolidinedione-6-aryl-pyridinones as Potent, Selective, and Orally Active EP3 Receptor Antagonists. |
TBA |
18359630 |
37 |
Identification of prostaglandin D2 receptor antagonists based on a tetrahydropyridoindole scaffold. |
Merck Frosst Canada |
18291643 |
76 |
Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor. |
Merck Frosst Centre For Therapeutic Research |
16931013 |
138 |
Comparison between two classes of selective EP(3) antagonists and their biological activities. |
Merck Frosst Centre For Therapeutic Research |
15914004 |
34 |
Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3. |
Fujisawa Pharmaceutical |
15357985 |
34 |
AL-12182, a novel 11-oxa prostaglandin analog with topical ocular hypotensive activity in the monkey. |
Alcon Research |
2909739 |
17 |
Prostaglandin photoaffinity probes: synthesis and biological activity of azide-substituted 16-phenoxy- and 17-phenyl-PGF2 alpha prostaglandins. |
University of Kentucky |
12643927 |
164 |
Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. |
Merck Frosst Centre For Therapeutic Research |
21208803 |
81 |
The identification of substituted benzothiophene derivatives as PGE(2) subtype 4 receptor antagonists: From acid to non-acid. |
Merck Frosst Centre For Therapeutic Research |
21036609 |
38 |
Potent and highly selective DP1 antagonists with 2,3,4,9-tetrahydro-1H-carbazole as pharmacophore. |
Merck Frosst Centre For Therapeutic Research |
20926294 |
65 |
3-Urea-1-(phenylmethyl)-pyridones as novel, potent, and selective EP3 receptor antagonists. |
Glaxosmithkline |
20471829 |
43 |
Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain. |
Merck Frosst Canada |
20303752 |
143 |
1,7-Disubstituted oxyindoles are potent and selective EP(3) receptor antagonists. |
Decode Chemistry |
19836233 |
31 |
Heterocyclic 1,7-disubstituted indole sulfonamides are potent and selective human EP3 receptor antagonists. |
Decode Chemistry |
20163116 |
116 |
The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist. |
Merck Frosst Centre For Therapeutic Research |
19592244 |
61 |
7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists. |
Novartis Institutes of Biomedical Research |
19487124 |
39 |
Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonists. |
Glaxosmithkline |
19332369 |
43 |
Discovery of sodium 6-[(5-chloro-2-{[(4-chloro-2-fluorophenyl)methyl]oxy}phenyl)methyl]-2-pyridinecarboxylate (GSK269984A) an EP(1) receptor antagonist for the treatment of inflammatory pain. |
Glaxosmithkline |
19307115 |
89 |
Discovery of potent and selective DP1 receptor antagonists in the azaindole series. |
Merck Frosst Centre For Therapeutic Research |
19188065 |
116 |
3-Acrylamide-4-aryloxyindoles: synthesis, biological evaluation and metabolic stability of potent and selective EP3 receptor antagonists. |
Decode Chemistry |
19121942 |
57 |
Peri-substituted hexahydro-indolones as novel, potent and selective human EP3 receptor antagonists. |
Decode Chemistry |
19036582 |
45 |
Discovery of GSK345931A: An EP(1) receptor antagonist with efficacy in preclinical models of inflammatory pain. |
Glaxosmithkline |
18701276 |
97 |
Highly functionalized 7-azaindoles as selective PPAR gamma modulators. |
Merck Research Laboratories |
17300164 |
62 |
Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). |
Merck Frosst Canada |
16529930 |
96 |
Identification of an indole series of prostaglandin D2 receptor antagonists. |
Merck Frosst Canada |
15935659 |
17 |
Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. |
Fujisawa Pharmaceutical |
15857112 |
55 |
Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. |
Fujisawa Pharmaceutical |
14552786 |
88 |
Structure-activity relationship of triaryl propionic acid analogues on the human EP3 prostanoid receptor. |
Merck Frosst Centre For Therapeutic Research |
12182865 |
88 |
Structure-activity relationship of biaryl acylsulfonamide analogues on the human EP(3) prostanoid receptor. |
Merck Frosst Centre For Therapeutic Research |
11708917 |
33 |
Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis. |
Procter & Gamble Pharmaceuticals |
11266183 |
32 |
Structure-activity relationship on the human EP3 prostanoid receptor by use of solid-support chemistry. |
Merck Frosst Canada |
10978187 |
4 |
Synthesis and biological activity of a novel 11a-homo (cyclohexyl) prostaglandin. |
Alcon Laboratories |
10915040 |
84 |
Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues. |
Procter & Gamble Pharmaceuticals |
10715159 |
112 |
Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor. |
Procter and Gamble Pharmaceuticals |
10509919 |
103 |
New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor. |
Merck Frosst Centre For Therapeutic Research |
29636218 |
43 |
Discovery of {4-[4,9-bis(ethyloxy)-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-2-fluorophenyl}acetic acid (GSK726701A), a novel EP |
Glaxosmithkline |
19317450 |
23 |
Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum. |
Harvard Medical School |
17824679 |
53 |
Novel 2,7-Dialkyl-Substituted 5(S)-Amino-4(S)-hydroxy-8-phenyl-octanecarboxamide Transition State Peptidomimetics Are Potent and Orally Active Inhibitors of Human Renin. |
Novartis Pharmaceuticals |
8057276 |
11 |
Crystal-structure-based design and synthesis of novel C-terminal inhibitors of HIV protease. |
Agouron Pharmaceuticals |